---
title: "Neurological Pathology"
order: 4
category: "Systemic Pathology"
---

# Neurological Pathology

## Overview

Neurological pathology encompasses diseases of the central nervous system (brain and spinal cord) and peripheral nervous system (peripheral nerves and ganglia). These disorders include cerebrovascular disease, neurodegenerative conditions, neoplasms, infectious diseases, demyelinating disorders, and traumatic injuries.

### Epidemiology
- **Stroke**: Leading cause of long-term disability, 3rd leading cause of death
- **Alzheimer's disease**: Most common neurodegenerative disorder, affects 6-7% >65 years
- **Brain tumors**: Account for ~2% of all cancers, significant morbidity
- **Multiple sclerosis**: Most common demyelinating disease in young adults
- **Increasing burden**: Aging population, improved diagnostic capabilities

## Cerebrovascular Disease

### Overview
Cerebrovascular diseases are the 3rd leading cause of death in developed countries and the leading cause of neurological disability. They result from abnormalities of blood vessels supplying the brain.

### Ischemic Stroke

#### Definition
Cerebral infarction resulting from inadequate blood supply to part of the brain.

#### Epidemiology
- **85% of all strokes** are ischemic
- Risk increases with age
- More common in men
- Higher incidence in African Americans

#### Risk Factors
**Modifiable**:
- Hypertension (most important)
- Atrial fibrillation (cardioembolic)
- Diabetes mellitus
- Hyperlipidemia
- Smoking
- Obesity
- Physical inactivity
- Excessive alcohol

**Non-modifiable**:
- Age (>55 years)
- Sex (men > women before age 75)
- Race (African Americans > Caucasians)
- Family history
- Prior stroke or TIA

#### Classification by Mechanism

**Thrombotic stroke** (40%):
- In situ thrombus formation
- Atherosclerosis of large vessels
  - Carotid bifurcation
  - Middle cerebral artery
  - Basilar artery
- Small vessel disease (lacunar infarcts)

**Embolic stroke** (30%):
- **Cardiogenic emboli** (majority):
  - Atrial fibrillation (most common source)
  - Mural thrombus (post-MI)
  - Valvular disease (mitral stenosis, endocarditis)
  - Paradoxical emboli (patent foramen ovale)
- **Arterial emboli**: Atherosclerotic plaques

**Lacunar infarcts** (20%):
- Small (<15 mm) infarcts
- Deep penetrating arteries
- Hypertensive arteriolosclerosis
- Locations: Basal ganglia, thalamus, pons, internal capsule

**Hypoperfusion/Watershed infarcts**:
- Global hypoperfusion (cardiac arrest, severe hypotension)
- Border zones between arterial territories
- Bilateral distribution

#### Vascular Territories
- **Anterior cerebral artery (ACA)**: Medial frontal and parietal lobes
- **Middle cerebral artery (MCA)**: Lateral frontal, parietal, temporal lobes (most common)
- **Posterior cerebral artery (PCA)**: Occipital lobe, medial temporal lobe
- **Basilar/vertebral arteries**: Brainstem, cerebellum
- **Watershed zones**: ACA-MCA, MCA-PCA boundaries

#### Pathophysiology

**Ischemic cascade**:
1. **Reduced perfusion** (CBF <20 mL/100g/min)
2. **Energy failure**: ATP depletion, Na+/K+ pump failure
3. **Depolarization**: Membrane potential loss
4. **Glutamate release**: Excitotoxicity
5. **Calcium influx**: Activates proteases, lipases, endonucleases
6. **Free radical generation**: Oxidative stress
7. **Mitochondrial damage**: Apoptosis pathways
8. **Cell death**: Necrosis and apoptosis

**Ischemic penumbra**:
- Surrounding zone of ischemic but viable tissue
- Salvageable with reperfusion
- Therapeutic target (thrombolysis, thrombectomy)

#### Temporal Evolution

**0-12 hours**:
- **Gross**: No visible changes or subtle blurring of gray-white junction
- **Microscopic**:
  - Red neurons (6-12 hours): Hypereosinophilic cytoplasm, pyknotic nuclei
  - Cytotoxic edema begins

**12-24 hours**:
- **Gross**: Blurred gray-white junction, swelling
- **Microscopic**: Red neurons, loss of neurons, neutrophil infiltration begins

**24-48 hours**:
- **Gross**: Pale, soft tissue, swelling
- **Microscopic**: Necrotic neurons, neutrophils, vascular proliferation

**2-10 days**:
- **Gross**: Gelatinous, friable tissue, maximal swelling (days 3-5)
- **Microscopic**: Macrophage infiltration, liquefactive necrosis
- **Risk**: Herniation from edema (days 2-4)

**10 days - 3 weeks**:
- **Gross**: Liquefaction, cavitation begins
- **Microscopic**: Macrophages with myelin debris (gitter cells), reactive astrocytes

**Weeks to months**:
- **Gross**: Cystic cavity with fluid
- **Microscopic**: Cystic cavity surrounded by gliosis
- **End result**: Fluid-filled cavity with astrocytic scar

#### Gross Pathology
**Acute** (hours to days):
- Soft, swollen, pale tissue
- Blurred gray-white junction
- Mass effect, sulcal effacement
- May have petechial hemorrhage (reperfusion)

**Subacute** (days to weeks):
- Gelatinous, friable
- Yellow-gray discoloration
- Beginning cavitation

**Chronic** (months):
- Cystic cavity
- Gliotic scar
- Hemosiderin staining (if hemorrhagic)
- Volume loss, ex vacuo ventriculomegaly

#### Microscopic Pathology
- **Acute**: Red neurons, neutrophils, cytotoxic edema
- **Subacute**: Macrophages (gitter cells), vascular proliferation
- **Chronic**: Cystic cavity, astrocytic gliosis (GFAP+), hemosiderin-laden macrophages

#### Clinical Features
- **Sudden onset** (minutes)
- **Focal neurological deficits** (territory-dependent):
  - MCA: Contralateral hemiparesis/hemianesthesia (face and arm > leg), aphasia (dominant hemisphere)
  - ACA: Contralateral leg weakness
  - PCA: Homonymous hemianopsia, memory deficits
  - Basilar: Cranial nerve palsies, ataxia, altered consciousness
- Headache (variable)
- Altered consciousness (large strokes)

#### Complications
- **Cerebral edema**: Days 2-4, herniation risk
- **Hemorrhagic transformation**: Reperfusion injury
- **Seizures**: 5-10% of patients
- **Hydrocephalus**: Obstructive (posterior fossa) or communicating
- **Chronic**: Cognitive decline, epilepsy, disability

### Hemorrhagic Stroke

#### Intracerebral Hemorrhage (ICH)

**Definition**: Bleeding directly into brain parenchyma

**Epidemiology**: 10-15% of all strokes, higher mortality than ischemic

**Etiology**:

**Hypertensive hemorrhage** (50%):
- Chronic hypertension → lipohyalinosis of penetrating arteries
- **Charcot-Bouchard microaneurysms**
- **Common locations**:
  - Basal ganglia (putamen) - 50%
  - Thalamus - 15%
  - Pons - 10%
  - Cerebellum - 10%
  - Lobar (subcortical white matter) - 15%

**Cerebral amyloid angiopathy (CAA)**:
- β-amyloid deposition in vessel walls
- Elderly patients (>60 years)
- **Lobar hemorrhages** (cortical-subcortical)
- Recurrent hemorrhages
- Associated with Alzheimer's disease
- ApoE ε2 and ε4 alleles increase risk

**Other causes**:
- Arteriovenous malformation (AVM)
- Coagulopathy (anticoagulants, thrombocytopenia)
- Tumor (melanoma, choriocarcinoma, renal cell, glioblastoma)
- Vasculitis
- Drug abuse (cocaine, amphetamines)
- Trauma
- Hemorrhagic transformation of infarct

**Pathology**:
- Hematoma in brain parenchyma
- Mass effect, displacement of structures
- Dissects along white matter tracts
- May rupture into ventricles (intraventricular hemorrhage)
- **Evolution**:
  - Acute: Fresh blood, clot
  - Days: Hemoglobin breakdown, hemosiderin
  - Weeks to months: Cavity with hemosiderin-stained walls

**Microscopic**:
- Extravasated RBCs
- Tissue disruption
- Edema
- Later: Hemosiderin-laden macrophages, gliosis

**Clinical**:
- Sudden onset headache, neurological deficits
- Altered consciousness (large hemorrhages)
- Nausea, vomiting
- Symptoms worsen over minutes to hours (expanding hematoma)
- Deficit depends on location

**Prognosis**: 30-50% mortality at 30 days

#### Subarachnoid Hemorrhage (SAH)

**Definition**: Bleeding into subarachnoid space

**Etiology**:

**Ruptured saccular (berry) aneurysm** (80%):
- Most common cause of non-traumatic SAH
- **Locations** (circle of Willis):
  - Anterior communicating artery (30%)
  - Posterior communicating artery (25%)
  - Middle cerebral artery bifurcation (20%)
  - Basilar artery (10%)
  - Vertebral artery (5%)
- **Risk factors**: Hypertension, smoking, ADPKD, Ehlers-Danlos type IV, family history
- Multiple aneurysms in 20-30%

**Arteriovenous malformation (AVM)**: 5%

**Trauma**: Common cause of SAH

**Other**: Vasculitis, coagulopathy, drug abuse

**Saccular aneurysm pathology**:
- **Congenital defect** in vessel wall (media)
- Degenerative changes from hemodynamic stress
- Loss of internal elastic lamina, thinned media
- Thin wall (adventitia and intima only)
- Outpouching from vessel
- Size: Few mm to >2 cm
- **Rupture risk**: Increases with size (>7-10 mm)

**Clinical features** (SAH):
- **"Worst headache of my life"**: Sudden, severe ("thunderclap")
- Nuchal rigidity (meningismus)
- Photophobia
- Altered consciousness
- Focal deficits (mass effect from hematoma)
- Seizures

**Complications**:
- **Rebleeding**: 20-30% in first 2 weeks (highest mortality)
- **Vasospasm**: Days 4-14, delayed ischemic deficit
- **Hydrocephalus**: Acute (obstructive) or delayed (communicating)
- **Hyponatremia**: SIADH, cerebral salt wasting

**Diagnosis**: CT (hyperdense blood in subarachnoid space), LP (xanthochromia if CT negative)

**Treatment**: Aneurysm clipping or endovascular coiling

**Prognosis**: 30-40% mortality, many survivors have disability

### Vascular Malformations

**Arteriovenous Malformation (AVM)**:
- Tangle of abnormal vessels (arteries directly to veins, no capillary bed)
- Congenital
- Can hemorrhage (2-4% per year)
- Seizures, headaches, focal deficits
- Pathology: Thickened vessels, gliotic brain, hemosiderin

**Cavernous Malformation (Cavernoma)**:
- Clusters of thin-walled, dilated vessels
- Low flow
- Hemorrhages (small, often asymptomatic)
- Seizures common
- Pathology: Back-to-back vessels, no intervening brain parenchyma

**Capillary Telangiectasia**:
- Dilated capillaries
- Pons most common
- Usually incidental, benign

## Neurodegenerative Diseases

### Alzheimer's Disease

#### Definition
Progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and behavioral changes.

#### Epidemiology
- **Most common cause of dementia** (60-70% of cases)
- Prevalence increases with age: 1-2% at 65, 20-30% at 85
- Women > men
- 50 million affected worldwide
- Major public health burden

#### Risk Factors
**Age**: Most important risk factor

**Genetics**:
- **Familial AD** (<5%, early onset):
  - APP (chromosome 21): β-amyloid precursor protein
  - PSEN1 (chromosome 14): Presenilin 1 (most common)
  - PSEN2 (chromosome 1): Presenilin 2
  - Autosomal dominant, age <65
- **Sporadic AD** (>95%):
  - **ApoE ε4 allele**: Strongest genetic risk factor
    - One copy: 3× risk
    - Two copies: 12× risk
    - Dose-dependent, earlier onset
  - ApoE ε2: Protective

**Other risk factors**:
- Cardiovascular risk factors (hypertension, diabetes, hyperlipidemia)
- Head trauma
- Low education
- Down syndrome (trisomy 21): Develop AD pathology by age 40

#### Pathogenesis

**Amyloid hypothesis** (dominant theory):
1. **APP processing**: Amyloid precursor protein (APP) on chromosome 21
2. **Abnormal cleavage**: β-secretase and γ-secretase → Aβ42 peptide (instead of normal α-secretase pathway)
3. **Aβ42 aggregation**: Oligomers (toxic) → fibrils → plaques
4. **Toxicity**: Oxidative stress, inflammation, synaptic dysfunction
5. **Tau hyperphosphorylation**: Secondary event
6. **Neurofibrillary tangles**: Paired helical filaments of tau
7. **Neuronal death**: Synaptic loss, neurodegeneration
8. **Dementia**: Cognitive decline

**Tau hypothesis**: Some argue tau pathology is primary driver

**Other mechanisms**: Inflammation, oxidative stress, mitochondrial dysfunction, cholinergic deficit

#### Gross Pathology
- **Cortical atrophy**: Diffuse, frontal and temporal lobes prominent
- **Sulcal widening**: Prominent sulci
- **Ventricular enlargement**: Ex vacuo hydrocephalus
- **Narrowed gyri**
- **Hippocampal atrophy**: Severe (memory center)
- **Reduced brain weight**: 1000-1100 g (normal ~1400 g)

#### Microscopic Pathology

**Amyloid (senile) plaques**:
- **Neuritic plaques**: Core of Aβ (extracellular), surrounded by dystrophic neurites, astrocytes, microglia
- **Diffuse plaques**: Aβ deposits without neuritic changes (may be precursor)
- **Staining**: Congo red (apple-green birefringence), thioflavin, immunohistochemistry (Aβ antibodies)
- Distribution: Neocortex, hippocampus, amygdala

**Neurofibrillary tangles (NFTs)**:
- **Intracellular** aggregates of hyperphosphorylated tau protein
- **Paired helical filaments** (PHF) by electron microscopy
- Flame-shaped in pyramidal neurons, globose in other neurons
- **Staining**: Silver stains (Bielschowsky), thioflavin, tau immunohistochemistry
- **Distribution**: Entorhinal cortex → hippocampus → neocortex
- **Braak staging**: I-II (entorhinal), III-IV (limbic), V-VI (neocortical)
- Persist as "ghost tangles" after neuron death

**Neuronal loss and gliosis**:
- Loss of neurons, especially in hippocampus and cortex
- Reactive astrocytosis

**Cerebral amyloid angiopathy (CAA)**:
- Aβ deposition in vessel walls
- Occurs in >80% of AD patients
- Risk of lobar hemorrhages

**Granulovacuolar degeneration**: Vacuoles in neurons (hippocampus)

**Hirano bodies**: Eosinophilic rod-like inclusions (actin)

#### Clinical Features
**Early stage**:
- Short-term memory loss (hallmark)
- Difficulty with new information
- Disorientation
- Mild language problems (word-finding)
- Preserved social skills initially

**Middle stage**:
- Progressive memory loss
- Aphasia, apraxia, agnosia
- Disorientation to time and place
- Impaired judgment
- Behavioral changes (wandering, aggression)
- Assistance needed for daily activities

**Late stage**:
- Severe cognitive impairment
- Loss of communication
- Loss of mobility
- Incontinence
- Complete dependence
- Bedridden

**Average duration**: 8-10 years from diagnosis to death

#### Diagnosis
- Clinical diagnosis (supportive testing)
- Neuropsychological testing
- MRI: Atrophy, especially hippocampus
- PET: Hypometabolism (FDG-PET), amyloid imaging (PIB-PET)
- CSF: Low Aβ42, high tau, high phospho-tau
- Definitive diagnosis: Postmortem neuropathology

#### Treatment
- **Acetylcholinesterase inhibitors**: Donepezil, rivastigmine (symptomatic)
- **NMDA antagonist**: Memantine (moderate to severe)
- **Aducanumab**: Anti-amyloid monoclonal antibody (controversial, modest benefit)
- Supportive care, behavioral management

### Parkinson's Disease

#### Definition
Progressive neurodegenerative disorder characterized by motor symptoms (tremor, rigidity, bradykinesia, postural instability) due to dopaminergic neuron loss in substantia nigra.

#### Epidemiology
- **Second most common neurodegenerative disease**
- Prevalence: 1-2% of population >60 years
- Mean age of onset: 60 years
- Men > women (1.5:1)
- 10 million affected worldwide

#### Etiology
**Sporadic** (90%): Unknown cause, likely multifactorial

**Genetic** (10%):
- **SNCA** (α-synuclein): Point mutations, duplications/triplications
- **LRRK2**: Most common genetic cause
- **Parkin, PINK1, DJ-1**: Autosomal recessive, early onset
- **GBA**: Glucocerebrosidase, increased risk

**Environmental risk factors**:
- Pesticides, herbicides
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
- Rural living, well water

**Protective factors**: Smoking, coffee (paradoxically)

#### Pathogenesis
- **Dopaminergic neuron loss** in substantia nigra pars compacta
- **α-Synuclein aggregation**: Misfolding → oligomers → fibrils
- **Lewy body formation**: Intracytoplasmic inclusions
- **Mitochondrial dysfunction**: Complex I deficiency
- **Oxidative stress**: Dopamine metabolism produces ROS
- **Neuroinflammation**: Microglial activation
- **Ubiquitin-proteasome dysfunction**: Impaired protein degradation

**Prion-like spread hypothesis**: α-Synuclein propagates from cell to cell (gut → brainstem → substantia nigra → cortex)

#### Gross Pathology
- **Depigmentation of substantia nigra**: Loss of melanin-containing neurons
- **Locus coeruleus**: Also depigmented
- Atrophy (mild or absent)

#### Microscopic Pathology

**Neuronal loss**:
- **Substantia nigra pars compacta**: Severe loss of dopaminergic neurons
- Locus coeruleus, dorsal motor nucleus of vagus
- Loss of neuromelanin-containing neurons

**Lewy bodies**:
- **Intracytoplasmic eosinophilic inclusions**
- Round, concentric laminated structures
- Dense core, pale halo
- **α-Synuclein** positive (immunohistochemistry)
- Ubiquitin positive
- Substantia nigra, locus coeruleus, cortex (Parkinson's disease dementia)

**Lewy neurites**: Dystrophic neurites containing α-synuclein

**Gliosis**: Reactive astrocytes and microglia

**Braak staging** (Lewy pathology progression):
- Stage 1-2: Medulla, olfactory bulb
- Stage 3-4: Substantia nigra, limbic system
- Stage 5-6: Neocortex

#### Clinical Features

**Motor symptoms (cardinal features)**:
- **Tremor**: Resting tremor, "pill-rolling", 4-6 Hz
- **Rigidity**: "Cogwheel" rigidity, increased tone
- **Bradykinesia**: Slowness of movement (most disabling)
- **Postural instability**: Falls, late feature

**Other motor features**:
- Hypomimia (masked facies)
- Micrographia (small handwriting)
- Shuffling gait
- Stooped posture
- Festinating gait
- Loss of arm swing

**Non-motor symptoms**:
- **Olfactory dysfunction**: Early, years before motor symptoms
- **REM sleep behavior disorder**: Acting out dreams
- **Autonomic**: Constipation, orthostatic hypotension, urinary dysfunction
- **Neuropsychiatric**: Depression, anxiety, apathy
- **Cognitive impairment**: Dementia in 30-40% (late)
- **Hallucinations**: Visual, often medication-related

**Clinical diagnosis**: UK Brain Bank criteria (bradykinesia + tremor or rigidity)

#### Treatment
- **Levodopa/carbidopa**: Most effective, "gold standard"
  - Dopamine precursor, crosses blood-brain barrier
  - Complications: Dyskinesias, motor fluctuations (after years)
- **Dopamine agonists**: Pramipexole, ropinirole
- **MAO-B inhibitors**: Selegiline, rasagiline
- **COMT inhibitors**: Entacapone
- **Anticholinergics**: Tremor
- **Amantadine**: Dyskinesias
- **Deep brain stimulation**: Advanced disease

**Prognosis**: Chronic progressive, 10-15 years typical course

### Amyotrophic Lateral Sclerosis (ALS)

#### Definition
Rapidly progressive neurodegenerative disease characterized by degeneration of upper motor neurons (cortex) and lower motor neurons (brainstem, spinal cord).

#### Epidemiology
- Prevalence: 5-7 per 100,000
- Incidence: 1-2 per 100,000 per year
- Mean age of onset: 55-65 years
- Men > women (1.5:1)
- Most common motor neuron disease in adults

#### Etiology
**Sporadic** (90%): Unknown

**Familial** (10%):
- **SOD1**: Superoxide dismutase 1 (20% of familial)
- **C9orf72**: GGGGCC repeat expansion (most common familial cause, 40%)
- **TDP-43, FUS**: RNA-binding proteins
- **TARDBP**

#### Pathogenesis
- Selective degeneration of motor neurons
- Mechanisms (multifactorial):
  - Glutamate excitotoxicity
  - Oxidative stress
  - Protein aggregation (SOD1, TDP-43, FUS)
  - Mitochondrial dysfunction
  - Neuroinflammation
  - Impaired axonal transport
  - Non-cell autonomous mechanisms (glial involvement)

#### Gross Pathology
- **Atrophy of precentral gyrus** (motor cortex)
- **Pallor of corticospinal tracts** (spinal cord)
- **Atrophy of anterior nerve roots**
- **Atrophy of motor nuclei** (brainstem, spinal cord)

#### Microscopic Pathology
- **Loss of motor neurons**: Anterior horn (spinal cord), motor nuclei (brainstem), Betz cells (cortex)
- **Corticospinal tract degeneration**: Myelin loss, gliosis
- **Inclusions**:
  - **Bunina bodies**: Eosinophilic inclusions in motor neurons (specific for ALS)
  - **TDP-43 inclusions**: Cytoplasmic, ubiquitin-positive (90% of cases)
  - SOD1 inclusions (in SOD1-mutated cases)
- **Astrocytosis**: Gliosis in affected areas
- **Muscle**: Denervation atrophy, grouped atrophy

#### Clinical Features

**Upper motor neuron signs**:
- Spasticity
- Hyperreflexia
- Extensor plantar response (Babinski sign)
- Loss of dexterity

**Lower motor neuron signs**:
- Muscle weakness, atrophy
- Fasciculations
- Hyporeflexia
- Flaccid paralysis

**Clinical patterns**:
- **Limb onset** (70%): Asymmetric weakness, progresses to other limbs
- **Bulbar onset** (25%): Dysarthria, dysphagia, tongue atrophy
- **Respiratory onset** (rare): Dyspnea

**Preserved functions**:
- Sensation intact
- Eye movements intact (except late)
- Bowel and bladder function intact
- Cognition usually intact (15% have frontotemporal dementia)

**Diagnosis**: Clinical + EMG (denervation, fasciculations), nerve conduction (normal)

**El Escorial criteria**: UMN + LMN signs in multiple regions

#### Treatment
- **Riluzole**: Glutamate antagonist, modest benefit (2-3 months survival)
- **Edaravone**: Free radical scavenger
- Supportive: Respiratory support, feeding tube, physical therapy

#### Prognosis
- Rapidly progressive
- **Median survival: 3-5 years from onset**
- 10-20% survive >10 years
- Respiratory failure is usual cause of death

### Huntington's Disease

#### Definition
Autosomal dominant neurodegenerative disorder characterized by chorea, cognitive decline, and psychiatric disturbances.

#### Genetics
- **Gene**: HTT (huntingtin) on chromosome 4
- **Mutation**: CAG trinucleotide repeat expansion
  - Normal: 10-35 repeats
  - HD: ≥36 repeats (40+ fully penetrant)
- **Autosomal dominant**: 50% transmission
- **Anticipation**: Paternal transmission → earlier onset, more severe (larger expansion)
- **Age of onset**: Inversely correlates with repeat number (more repeats → earlier onset)

#### Pathogenesis
- Mutant huntingtin protein (polyglutamine expansion)
- Protein misfolding and aggregation
- Intranuclear inclusions
- Transcriptional dysregulation
- Excitotoxicity (glutamate)
- Mitochondrial dysfunction
- Selective vulnerability of medium spiny neurons in striatum (caudate, putamen)

#### Gross Pathology
- **Atrophy of caudate nucleus**: Hallmark, loss of normal bulge into lateral ventricle
- **Atrophy of putamen**
- **Ventricular enlargement**: Compensatory (ex vacuo)
- Cortical atrophy (late)
- Reduced brain weight

#### Microscopic Pathology
- **Loss of medium spiny neurons** in striatum (GABAergic)
- **Sparing of interneurons** and large neurons initially
- **Gliosis**: Reactive astrocytes
- **Intranuclear inclusions**: Huntingtin aggregates, ubiquitin-positive
- Cortical neuronal loss (late)

**Grading** (Vonsattel): 0-4 based on striatal pathology

#### Clinical Features
**Motor symptoms**:
- **Chorea**: Involuntary, irregular, dance-like movements (hallmark)
  - Initially subtle (fidgeting)
  - Progresses to severe, disabling
- Dystonia
- Bradykinesia (late)
- Rigidity (late, juvenile-onset)
- Gait disturbance, falls
- Dysarthria, dysphagia

**Cognitive symptoms**:
- Executive dysfunction
- Impaired attention, concentration
- Slowed processing
- Memory deficits (retrieval > encoding)
- Progressive dementia

**Psychiatric symptoms** (often earliest):
- Depression (common, suicide risk)
- Irritability, aggression
- Apathy
- Anxiety
- Psychosis (less common)

**Typical onset**: Age 30-50 years

**Juvenile HD** (<20 years): Rigidity, bradykinesia > chorea (Westphal variant)

#### Diagnosis
- Clinical features + family history
- **Genetic testing**: CAG repeat expansion (definitive)
- MRI: Caudate atrophy

#### Treatment
- **Symptomatic**:
  - Chorea: Tetrabenazine, deutetrabenazine (VMAT2 inhibitors)
  - Psychiatric: Antidepressants, antipsychotics
- Supportive care

#### Prognosis
- Relentlessly progressive
- Average duration: 15-20 years from onset
- Death from complications (pneumonia, falls, suicide)

## Demyelinating Diseases

### Multiple Sclerosis (MS)

#### Definition
Chronic autoimmune demyelinating disease of the CNS characterized by disseminated white matter lesions separated in time and space.

#### Epidemiology
- Most common demyelinating disease
- Prevalence: 50-300 per 100,000 (varies by latitude)
- **Latitude gradient**: Higher prevalence farther from equator
- Age of onset: 20-40 years (peak ~30)
- Women > men (2-3:1)
- Caucasians > other races

#### Pathogenesis
**Autoimmune disease**:
- Autoreactive T cells (CD4+ Th1, Th17) against myelin antigens
- Cross blood-brain barrier
- Release cytokines (IFN-γ, IL-17, TNF-α)
- Macrophage and microglial activation
- B cells and antibodies
- Complement activation
- Demyelination and axonal injury

**Genetic susceptibility**:
- HLA-DR2 (DRB1*15:01) strongest association
- >200 susceptibility loci (mostly immune-related genes)

**Environmental triggers**:
- Epstein-Barr virus (strong association)
- Vitamin D deficiency
- Smoking
- Childhood infections
- Migration studies (acquire risk of new location if migrate before adolescence)

#### Gross Pathology
- **Plaques**: Well-demarcated areas of demyelination
- **Distribution**:
  - Periventricular white matter (characteristic)
  - Optic nerves
  - Brainstem
  - Cerebellum
  - Spinal cord (lateral and posterior columns)
- **Appearance**:
  - Acute: Soft, pink-gray
  - Chronic: Firm, gray, glassy (gliosis)
- **Dawson's fingers**: Perivenular plaques perpendicular to ventricles

#### Microscopic Pathology
**Active plaque**:
- **Demyelination**: Loss of myelin (LFB stain), relative axonal preservation (silver stain)
- **Perivenular inflammation**: Lymphocytes, macrophages
- **Macrophages with myelin debris**: Foamy cytoplasm
- Reactive astrocytes
- Axonal injury (variable)

**Chronic active plaque**:
- Inactive center (gliosis)
- Active edge (ongoing demyelination, macrophages)

**Inactive (chronic) plaque**:
- Complete demyelination
- **Gliosis**: Dense astrocytic scar (GFAP+)
- Hypocellular
- Axonal loss (variable)
- No inflammation

**Shadow plaques**: Incomplete remyelination (thin myelin)

#### Clinical Features

**Clinical patterns**:
- **Relapsing-remitting** (85% at onset):
  - Discrete attacks (relapses) followed by recovery (complete or partial)
  - Stable between attacks
  - Eventually → secondary progressive in most
- **Primary progressive** (10-15%):
  - Gradual worsening from onset
  - No relapses
  - Older age, more males
- **Secondary progressive**:
  - Follows relapsing-remitting
  - Progressive worsening with or without superimposed relapses
- **Progressive-relapsing** (rare):
  - Progressive from onset with acute relapses

**Common presenting symptoms**:
- **Optic neuritis**: Unilateral vision loss, eye pain, central scotoma
- **Sensory disturbances**: Paresthesias, numbness
- **Motor weakness**: Limb weakness, spasticity
- **Brainstem/cerebellar**: Diplopia, ataxia, vertigo, dysarthria
- **Spinal cord**: Lhermitte's sign (electric shock sensation down spine with neck flexion)
- **Bladder dysfunction**: Urgency, frequency, retention

**Later symptoms**:
- Fatigue (very common)
- Cognitive impairment
- Depression
- Heat sensitivity (Uhthoff's phenomenon)
- Trigeminal neuralgia
- Sexual dysfunction

#### Diagnosis
**McDonald criteria** (2017 revision):
- **Dissemination in space**: Multiple CNS lesions
- **Dissemination in time**: Lesions at different times
- **MRI**: White matter lesions (T2/FLAIR hyperintense, Dawson's fingers)
- **CSF**: Oligoclonal bands (IgG) not present in serum (90%)
- **Evoked potentials**: Delayed (optic, somatosensory, auditory)

#### Treatment
**Acute relapse**: High-dose corticosteroids (methylprednisolone)

**Disease-modifying therapies**:
- **Injectable**: Interferon-β, glatiramer acetate
- **Oral**: Fingolimod, dimethyl fumarate, teriflunomide, cladribine
- **Infusion**: Natalizumab, ocrelizumab, alemtuzumab, rituximab
- Newer agents target B cells, S1P receptors, α4-integrin

**Symptomatic**: Spasticity, pain, bladder dysfunction, fatigue

#### Prognosis
- Variable, unpredictable
- Average life expectancy reduced by 5-10 years
- Relapses usually within first years
- Disability accumulation over time
- Better prognosis: Young age, female, RRMS, optic neuritis/sensory onset

## CNS Neoplasms

### Overview
**Epidemiology**:
- Primary CNS tumors: ~2% of all cancers
- Metastases more common than primary tumors
- Bimodal age distribution: Children (medulloblastoma, pilocytic astrocytoma) and elderly (glioblastoma)

**Classification**: 2021 WHO Classification integrates histology and molecular features

### Gliomas

#### Glioblastoma (WHO Grade 4)

**Most common primary malignant brain tumor in adults** (50% of gliomas)

**Epidemiology**:
- Peak age: 60-70 years
- Men > women (1.5:1)
- Most common in cerebral hemispheres

**Classification**:
- **Glioblastoma, IDH-wildtype** (90%): Primary, older patients, worse prognosis
- **Glioblastoma, IDH-mutant** (10%): Secondary (progression from lower-grade glioma), younger patients, better prognosis

**Molecular features**:
- **IDH status**: Wildtype (90%) vs. mutant (10%)
- **MGMT promoter methylation**: Predicts response to temozolomide (30-40%)
- **EGFR amplification**: IDH-wildtype (40%)
- **TERT promoter mutation**: IDH-wildtype (80%)
- **TP53 mutation**: IDH-mutant
- **ATRX loss**: IDH-mutant

**Gross pathology**:
- **Infiltrative**, poorly demarcated mass
- **Variegated appearance**: Hemorrhage, necrosis, cysts
- Crosses midline (butterfly glioma)
- Expands, distorts brain

**Microscopic pathology**:
- **Hypercellularity**: Pleomorphic, atypical astrocytes
- **Necrosis**: Coagulative, geographic, **pseudopalisading** (hallmark)
- **Microvascular proliferation**: Glomeruloid tufts (hallmark)
- **High mitotic activity**: Atypical mitoses
- **Infiltrative**: Invades along white matter tracts, blood vessels
- **GFAP positive** (variable)

**Clinical**:
- Headache, seizures, focal deficits
- Rapidly progressive (weeks to months)
- Increased intracranial pressure

**Treatment**:
- Surgery (maximal safe resection)
- Radiation therapy
- Temozolomide (chemotherapy)

**Prognosis**:
- **Dismal**: Median survival 12-15 months (IDH-wildtype)
- IDH-mutant: ~24 months
- 5-year survival <10%

#### Astrocytoma, IDH-mutant (WHO Grades 2-4)

**Definition**: Diffusely infiltrating astrocytic tumor with IDH mutation

**Molecular hallmark**:
- **IDH1 or IDH2 mutation** (required for diagnosis)
- **TP53 mutation** (common)
- **ATRX loss** (common)
- **1p/19q intact** (not co-deleted)

**Grading** (CNS WHO 2021):
- Grade 2: Low cellularity, no mitoses, no necrosis, no MVT
- Grade 3: Increased cellularity, mitoses, no necrosis
- Grade 4: Necrosis and/or microvascular proliferation

**Clinical**:
- Younger patients (mean age 35-45)
- Seizures common presenting symptom
- Slow progression (years)
- Inevitable progression to higher grade (glioblastoma)

**Prognosis**:
- Grade 2: Median survival 10-15 years
- Grade 3: Median survival 5-7 years
- Grade 4: Median survival 2-3 years (better than IDH-wildtype)

#### Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (WHO Grades 2-3)

**Definition**: Diffusely infiltrating glial tumor with IDH mutation and 1p/19q codeletion

**Molecular hallmarks** (required for diagnosis):
- **IDH1 or IDH2 mutation**
- **1p/19q codeletion** (whole-arm loss)
- **TERT promoter mutation** (common)
- **CIC and FUBP1 mutations** (common)

**Gross pathology**:
- Gelatinous, soft
- Frontal lobe predilection
- Cortical/subcortical

**Microscopic pathology**:
- **"Fried egg" appearance**: Round nuclei, clear perinuclear halo (artifact in formalin-fixed tissue)
- Uniform, round nuclei
- **Chicken-wire vasculature**: Branching capillaries
- **Calcification**: Common
- **Cortical infiltration**

**Grading**:
- Grade 2: Low mitotic activity
- Grade 3 (Anaplastic): Increased mitoses, proliferation, necrosis

**Clinical**:
- Seizures (most common presentation)
- Younger adults (mean age 40-50)

**Prognosis**:
- **Best prognosis of diffuse gliomas**
- **Chemosensitive**: PCV (procarbazine, lomustine, vincristine)
- Grade 2: Median survival >10 years
- Grade 3: Median survival 7-10 years

#### Pilocytic Astrocytoma (WHO Grade 1)

**Most common brain tumor in children**

**Location**:
- Cerebellum (most common)
- Optic pathway (associated with NF1)
- Hypothalamus/thalamus
- Brainstem

**Molecular**:
- **BRAF alterations** (>80%):
  - KIAA1549-BRAF fusion (most common)
  - BRAF V600E mutation
- Activates MAPK pathway

**Gross pathology**:
- Well-circumscribed, cystic mass with mural nodule
- Non-infiltrative

**Microscopic pathology**:
- **Biphasic pattern**: Compact areas with Rosenthal fibers, loose areas with microcysts
- **Rosenthal fibers**: Eosinophilic, corkscrew-shaped (compact areas)
- **Eosinophilic granular bodies** (loose areas)
- Piloid (hair-like) processes
- Low mitotic activity
- GFAP positive

**Clinical**:
- Depends on location (cerebellar → ataxia, hydrocephalus)
- Slow growing

**Prognosis**:
- **Excellent** if completely resected
- 10-year survival >90%
- Rarely transforms to higher grade

### Ependymoma

**Definition**: Tumor arising from ependymal cells lining ventricles and central canal

**Location**:
- **Children**: Posterior fossa (4th ventricle), 70%
- **Adults**: Spinal cord, 60%
- Supratentorial (less common)

**Molecular groups** (posterior fossa):
- **PFA** (group A): Young children, worse prognosis
- **PFB** (group B): Older children, better prognosis

**Microscopic pathology**:
- **Perivascular pseudorosettes**: Tumor cells radiate around blood vessels with fibrillary processes (hallmark)
- **Ependymal rosettes**: True rosettes with central lumen (less common, specific)
- Uniform cells, round nuclei
- GFAP positive (variable)

**Grading**:
- Grade 2: Standard ependymoma
- Grade 3: Anaplastic (high mitotic rate, necrosis)

**Clinical**: Hydrocephalus (posterior fossa), symptoms of increased ICP

**Prognosis**: Variable, depends on extent of resection, grade, molecular group

### Medulloblastoma

**Most common malignant brain tumor in children**

**Location**: Posterior fossa (cerebellum, 4th ventricle)

**Peak age**: Bimodal (3-4 years, 8-10 years), also young adults

**Molecular subgroups** (WHO 2021):
- **WNT-activated**: Best prognosis (>95% survival)
- **SHH-activated**: Variable prognosis (depends on TP53 status)
- **Group 3**: Worst prognosis, MYC amplification
- **Group 4**: Intermediate prognosis

**Microscopic pathology**:
- **Highly cellular**: "Small blue cell tumor"
- **Sheets of cells**: Small, hyperchromatic nuclei, scant cytoplasm
- **Homer Wright rosettes**: Neuroblastic rosettes (some cases)
- High mitotic rate
- Necrosis common
- May have desmoplasia (SHH subgroup)

**Clinical**:
- Hydrocephalus (compression of 4th ventricle)
- Cerebellar signs (ataxia, dysmetria)
- Headache, vomiting (increased ICP)
- **CSF dissemination** (30%): Spinal drop metastases

**Prognosis**:
- Risk stratification: Age, extent of resection, metastases, molecular subgroup
- Standard risk: 70-80% 5-year survival
- High risk: 50-60% 5-year survival
- WNT subgroup: >95% survival

### Meningioma

**Most common primary intracranial tumor in adults**

**Origin**: Meningothelial (arachnoid cap) cells

**Location**:
- Convexities
- Parasagittal/falx
- Sphenoid wing
- Olfactory groove
- Spinal cord (intradural, extramedullary)

**Molecular**:
- **NF2 loss/mutation** (40-60%, especially Grade 2-3)
- **AKT1 mutation** (meningothelial subtype)
- **SMO mutation** (meningothelial subtype)
- **TRAF7, KLF4, PIK3CA mutations**

**Gross pathology**:
- Well-circumscribed, dural-based mass
- Compression (not invasion) of brain
- May have hyperostosis of adjacent bone

**Microscopic pathology**:

**Grade 1 (80-85%)**:
- **Meningothelial**: Whorls, syncytial sheets
- **Fibrous**: Spindle cells, collagen
- **Transitional (mixed)**: Whorls and fascicles
- **Psammomatous**: Abundant psammoma bodies
- **Psammoma bodies**: Laminated calcifications

**Grade 2 (15-20%)**:
- Increased mitoses (4-19 per 10 HPF)
- Brain invasion
- Atypical (≥3 of: sheeting, macronucleoli, hypercellularity, small cells, necrosis)

**Grade 3 (<3%)**:
- Malignant features: High mitoses (≥20 per 10 HPF), anaplasia, sarcomatous/carcinomatous appearance

**Clinical**:
- Often asymptomatic (incidental)
- Seizures, headache, focal deficits
- Slow growing

**Treatment**: Surgical resection (curative if complete)

**Prognosis**:
- Grade 1: Excellent, low recurrence if completely resected
- Grade 2: Higher recurrence risk (~40% at 10 years)
- Grade 3: High recurrence, poor prognosis

### Metastatic Brain Tumors

**More common than primary brain tumors** (10:1 ratio)

**Common primary sites**:
- Lung (50%, most common)
- Breast (15-20%)
- Melanoma (10%, highest propensity to metastasize to brain)
- Renal cell carcinoma (5-10%)
- Colon (5%)

**Location**:
- Gray-white junction (80%): Vascular watershed zones
- Cerebellum (15%)
- Multiple (50-70% of cases)

**Pathology**:
- Well-demarcated, spherical masses
- Extensive vasogenic edema (white matter)
- Necrosis central
- Hemorrhage (melanoma, renal cell, choriocarcinoma, thyroid)

**Clinical**: Similar to primary tumors (headache, seizures, focal deficits)

**Treatment**: Surgery, radiation (SRS or WBRT), chemotherapy (based on primary)

**Prognosis**: Generally poor, depends on primary, extent, number of metastases

## Key Points

### Cerebrovascular Disease
- Stroke is 3rd leading cause of death and leading cause of disability
- Ischemic stroke (85%) due to thrombosis, embolism, or hypoperfusion
- Hemorrhagic stroke (15%): ICH from hypertension or CAA; SAH from aneurysm rupture
- Temporal evolution of infarction is diagnostically important

### Neurodegenerative Diseases
- Alzheimer's: Amyloid plaques and neurofibrillary tangles; most common dementia
- Parkinson's: Substantia nigra degeneration, Lewy bodies; motor symptoms
- ALS: Upper and lower motor neuron loss; rapidly progressive, fatal
- Huntington's: CAG repeat expansion, caudate atrophy, chorea

### Demyelinating Diseases
- Multiple sclerosis: Autoimmune demyelination, plaques in CNS
- Relapsing-remitting most common pattern
- Periventricular white matter involvement characteristic
- CSF oligoclonal bands in 90%

### CNS Neoplasms
- Glioblastoma: Most common malignant primary brain tumor in adults; dismal prognosis
- Molecular classification (IDH, 1p/19q) guides diagnosis and prognosis
- Oligodendroglioma (IDH-mutant, 1p/19q-codeleted): Best prognosis of diffuse gliomas
- Pilocytic astrocytoma: Most common childhood brain tumor; excellent prognosis
- Meningioma: Most common primary intracranial tumor; usually benign
- Metastases more common than primary tumors in adults

## References

1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Elsevier; 2021. Chapter 28: The Central Nervous System.

2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251.

3. Ellison DW, Aldape KD, Capper D, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. 2020;30(5):863-866.

4. Love S, Budka H, Ironside JW, Perry A. Greenfield's Neuropathology. 9th ed. CRC Press; 2015.

5. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2019;50(12):e344-e418.

6. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032-2060.

7. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.

8. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601.

9. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299.

10. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
